Latest SEC Filings

Theriva Biologics, Inc.Theriva Biologics Reports Reduced Net Loss and Strategic Developments in Oncology

MAGELLAN COPPER & GOLD CorpMagellan Copper & Gold Corp. Reports $238,586 Net Loss for Q2 2026

Protara Therapeutics, Inc.Protara Therapeutics Reports $21.7 Million Net Loss in Q2 2026, Driven by Increased Operating Expenses

LB PHARMACEUTICALS INCLB Pharmaceuticals Reports $51.6 Million Net Loss in Q2 2026, Driven by R&D Expenses

DPC Holdings LtdDPC Holdings Reports 33.7% Revenue Growth in Q2 2026, Net Loss Widens

Theravance Biopharma, Inc.Theravance Biopharma Reports $5.9 Million Net Loss and Announces Merger with Zymeworks

Coya Therapeutics, Inc.Coya Therapeutics Reports 49% Increase in Collaboration Revenue for Q2 2026

SMITHFIELD FOODS INCSmithfield Foods Reports Q2 2026 Sales Decline but Net Income Increase

BIG SKY INDUSTRIAL INC.Big Sky Industrial Reports Improved Net Loss and Revenue Growth in Q2 2026

Prelude Therapeutics IncPrelude Therapeutics Reports $5.7 Million Revenue in Q2 2026, Continues to Operate at a Loss

Sagimet Biosciences Inc.Sagimet Biosciences Reports $13.9 Million Net Loss in Q2 2026

Zura Bio LtdZura Bio Reports $26.3 Million Net Loss and Increased R&D Expenses in Latest 10-Q Filing

C4 Therapeutics, Inc.C4 Therapeutics Reports Q2 2026 Revenue of $6.6 Million and Net Loss of $23.6 Million

Xtant Medical Holdings, Inc.Xtant Medical Reports 35% Revenue Decline and $9.4 Million Net Loss in Q2 2026

Aura Biosciences, Inc.Aura Biosciences Reports $45.6 Million Net Loss and Significant Asset Growth in Latest 10-Q

INTENSITY THERAPEUTICS, INC.Intensity Therapeutics Reports $3 Million Net Loss in Q2 2026, Highlights Clinical Advancements

Upstream Bio, Inc.Upstream Bio Reports Q2 2026 Financial Results with Revenue Decline and Increased Net Loss

Tango Therapeutics, Inc.Tango Therapeutics Reports Increased Losses and Significant Cash Reserves in Latest Financial Filing

Kardigan, Inc.Kardigan Reports $116.2 Million Net Loss and Completes IPO Raising $422.4 Million

Vestis CorpVestis Corporation Reports $661.7 Million Revenue and $11 Million Net Income for Quarter Ending July 3, 2026

Chicago Atlantic Real Estate Finance, Inc.Chicago Atlantic Real Estate Finance Reports Decline in Revenue and Net Income for Q2 2026

Neuraxis, INCNeurAxis Reports 115.7% Revenue Growth to $1.93 Million in Q2 2026

Shattuck Labs, Inc.Shattuck Labs Reports $15.2 Million Net Loss in Q2 2026, No Revenue Generated

IMMUNIC, INC.Immunic Reports $34.1 Million Net Loss and Advances Clinical Trials in Latest 10-Q Filing

Twenty One Capital, Inc.Twenty One Capital Reports $413.5 Million Net Loss in Q2 2026